Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Elite Pharmaceuticals (otcqb: ELTP) = CASH FLOW POSITIVE for about 2 years now with low debt. Unbelievably suppressed stock price @ 4 cents. Year 2021 revenue is $32 Million. Income from Operations before taxes is $6.3 Million. Net income attributable to common shareholders is $8.9 Million. CEO owns 300 million shares. ELTP historically made couple of Millionaire-making monster runs.
Outstanding Shares: 1.01 Billion
Float : ~ 750 Million
Latest SEC 10-K Financial Report
https://www.sec.gov/ix?doc=/Archives/edgar/data/1053369/000149315222018108/form10-k.htm
Will another Millionaire Maker run coming?
2010-2011........................... $0.039- $0.26
2014...................................... $0.060- $0.97
2022-2023........................... $0.035- DollarLand?
Catalysts:
2 abuse deterrents
generic CNS stimulant
ADF adderall
Very rare to find an otc listed company with CASH FLOW POSITIVE status.
GOVX was once an otc listed entity. Elite Pharmaceuticals (otcqb: ELTP) = CASH FLOW POSITIVE for about 2 years now with low debt. Unbelievably suppressed stock price @ 4 cents. Year 2021 revenue is $32 Million. Income from Operations before taxes is $6.3 Million. Net income attributable to common shareholders is $8.9 Million. CEO owns 300 million shares. ELTP historically made couple of Millionaire-making monster runs.
Outstanding Shares: 1.01 Billion
Float : ~ 750 Million
Latest SEC 10-K Financial Report
https://www.sec.gov/ix?doc=/Archives/edgar/data/1053369/000149315222018108/form10-k.htm
Will another Millionaire Maker run coming?
2010-2011........................... $0.039- $0.26
2014...................................... $0.060- $0.97
2022-2023........................... $0.035- DollarLand?
Catalysts:
2 abuse deterrents
generic CNS stimulant
ADF adderall
Very rare to find an otc listed company with CASH FLOW POSITIVE status.
Elite Pharmaceuticals (otcqb: ELTP) = CASH FLOW POSITIVE for about 2 years now with low debt. Unbelievably suppressed stock price @ 4 cents. Year 2021 revenue is $32 Million. Income from Operations before taxes is $6.3 Million. Net income attributable to common shareholders is $8.9 Million. CEO owns 300 million shares. ELTP historically made couple of Millionaire-making monster runs.
Outstanding Shares: 1.01 Billion
Float : ~ 750 Million
Latest SEC 10-K Financial Report
https://www.sec.gov/ix?doc=/Archives/edgar/data/1053369/000149315222018108/form10-k.htm
Will another Millionaire Maker run coming?
2010-2011........................... $0.039- $0.26
2014...................................... $0.060- $0.97
2022-2023........................... $0.035- DollarLand?
Catalysts:
2 abuse deterrents
generic CNS stimulant
ADF adderall
Very rare to find an otc listed company with CASH FLOW POSITIVE status.
Hi! Check on ELTP. CASH FLOW POSITIVE @ extremely suppressed price below a nickel !!!
Elite Pharmaceuticals (otcqb: ELTP) = CASH FLOW POSITIVE for about 2 years now with low debt. Unbelievably suppressed stock price @ 4 cents. Year 2021 revenue is $32 Million. Income from Operations before taxes is $6.3 Million. Net income attributable to common shareholders is $8.9 Million. CEO owns 300 million shares. ELTP historically made couple of Millionaire-making monster runs.
Outstanding Shares: 1.01 Billion
Float : ~ 750 Million
Latest SEC 10-K Financial Report
https://www.sec.gov/ix?doc=/Archives/edgar/data/1053369/000149315222018108/form10-k.htm
Will another Millionaire Maker run coming?
2010-2011........................... $0.039- $0.26
2014...................................... $0.060- $0.97
2022-2023........................... $0.035- DollarLand?
Catalysts:
2 abuse deterrents
generic CNS stimulant
ADF adderall
Very uncommon to find an otc listed company with CASH FLOW POSITIVE status.
"New investors starting to discover the Jewel of the OTC"
Indeed and more to come!
Nice gobble...gobble...gobbling up shares action !!! :))
With the $12 Mil loan we just got from the bank, I don't think we're tapping that $$$ from LPC anytime soon.
Are there any "termination clause" in the agreement?
That's right! Thanks to aELmTPa's dd.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169373550
4th time request! Any Moderator to kindly update the Financial Ibox. Please! Thank you!
Noted. Thank you!
It's a proposed treatment for addictive disorder with the focus on smoking tobacco.
"Considering the general role of dopamine transmission in substance use disorder, I expect that administration of PDE7 inhibitors would also reduce the motivation of other drugs of abuse, such as opioids, psychostimulants and alcohol.” --- This is just an expectation without any scientific proof ( human clinical trials ).
Now if you're thinking of incorporating it on an abuse deterrent drug formulation? Is it even feasible considering the resulting unknown side effects?
What does Phosphodiesterase 7 (PDE7), a cAMP-specific PDE family has to do to combat addiction? Can you provide any supporting scientific findings ( clinical trials )?
What is a phosphodiesterase inhibitor used for?
Phosphodiesterase inhibitors are class medications used in the management and treatment of chronic obstructive pulmonary disease(COPD), erectile dysfunction(ED), pulmonary arterial hypertension(PAH), benign prostatic hyperplasia(BPH), acute decompensated heart failure, psoriasis, psoriatic arthritis(PA), atopic ...Mar 16, 2022
3rd time request! Any Moderator to kindly update the Financial Ibox. Please! Thank you!
Right Timing!
Oxycodone Hydrochloride extended release (generic version of OxyContin®)
On September 20, 2017, the Company filed an ANDA with the FDA for generic version of OxyContin® (extended release Oxycodone Hydrochloride). OxyContin® is approved for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. IMS reported approximately $2.3 billion in revenue for OxyContin® and its equivalents in 2016. The FDA requested additional information relating to this filing, compliance with which would require significant resources. Development of this product has been reinitiated with a target filing in Q1 2023 --- Latest 10-K filing
Heck! I can easily bring it UP to a dime if I want to.LOL
Latest Conference Call Transcript
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169290156
I will not and have resisted for years going to NASDAQ on the fundamentals we have. Because if we do have a reversal split whether it’s 10 or 20, whatever it is to get us to NASDAQ and then when we get there, we don’t have the right fundamentals and we gravitate back to the OTC Board, everybody at the sound of my voice would lose 10 to 20-fold their investment, okay. And that could happen very easily. This is why even though it’s lucrative and you would be in NASDAQ for a short period of time and it’s not the right thing for any of us unless we get to the right fundamentals. And if it happens, it happens, it happens tomorrow fine. It happens in 100 years fine. I am not going to do it and risk the company going through what a lot of companies going through and that is gravitating back to the bulletin board. - Nasrat
Mods care to update the Financial IBox ? tia
Not aware of such reaction today but accumulation?
Beware! Seems some misinformation is being brought up regarding what is said in today's cc. Wait for the cc transcript!
Enough of this! No one is perfect = People makes mistakes
Well done summarizing!!! Thanks!
Great CC !!!
Still working with Dexcel to launch is Israel diligently!
NO CRL !!!!
New Drug Approval 100% owned by ELITE !!!!
Did I hear it correctly? 50% discount on buying the building.
Nice! lol
Can't sell "imaginary" shares :D
What is the market value for 135 Ludlow Avenue?
The market value* for 135 Ludlow Avenue in 2022 was $2,200,700.
Property Type
Industrial - Warehouse/Distribution
Property Size
35,000 SF
Property Tax in 2022
$66,593
Assessed Value
$2,200,700
Market Value*
$2,200,700
*This represents the market value determined by the appropriate local tax/financial authority, and not the latest sale price or current market value based on recent sales.[https://www.commercialcafe.com/commercial-property/us/nj/northvale/135-ludlow-avenue/
Good price versus annual $1 mil (?) lease.
Why the silence on a great ER? Aren't we supposed to make a buzz out of it? I guess for some trying to put ELTP out of expose' to prevent a run??? We'll see...
Employees
As of June 15, 2022, we had 43 full time employees. Full-time employees are engaged in operations, administration, research, and development. None of our employees is represented by a labor union and we have never experienced a work stoppage. We believe our relationship with our employees to be good. However, our ability to achieve our financial and operational objectives depends in large part upon our continuing ability to attract, integrate, retain, and motivate highly qualified personnel, and upon the continued service of our senior management and key personnel.
Acetaminophen and Codeine Phosphate
The Company received approval on September 10, 2019 from the FDA of an ANDA for a generic version of Tylenol® with Codeine (acetaminophen and codeine phosphate) 300mg/7.5mg, 300mg/15mg, 300mg/30mg and 300mg/60mg tablets. Acetaminophen with codeine is a combination medication indicated for the management of mild to moderate pain, where treatment with an opioid is appropriate and for which alternative treatments are inadequate. Acetaminophen with codeine products have annual U.S. sales of approximately $45 million according to IQVIA (formerly QuintilesIMS Health Data). The Company is not pursuing licensing deals for any opioids at this time until the market changes. The Company will wait for the market to stabilize before pursuing these opportunities.
I remember somebody here was claiming this product has been sold :p
I see desperation starts kicking in. What a life!
NOTE 19. SUBSEQUENT EVENTS
On April 2, 2022, the Company entered into a loan and security agreement with East West Bank, pursuant to which the Company was granted by the Bank a term loan of $12,000,000 for a duration of five years and an asset-based Revolving Line of Credit up to $2,000,000. The Company has received the proceeds of $11,959,880 out of the term loan net of applicable professional changes, and it will be used for general working capital purpose. In return for the term loan, the Company is required to meet certain financial terms and conditions.
On April 8, 2022, the Company entered into an Asset Purchase Agreement to purchase the building located at 135-137 Ludlow Avenue in Northvale NJ and is currently in escrow. The Company has leased the entire 35,000 square feet of floor space since 2014. This property is occupied by the Company’s Quality Assurance department, commercial manufacturing, packaging, and warehouse. The closing date is expected to take place in July 2022.
On June 27, 2022, the Company received notification from the US Food and Drug Administration (FDA) for the approval of the Company’s Abbreviated New Drug Application (ANDA) for a generic version of Sabril® (Vigabatrin USP) 500 mg powder for solution packet. Lannett Company, Inc. has an exclusive license to market and distribute the product in the U.S. and territories. Elite will exclusively manufacture and package the product for sale for an agreed-upon transfer price. The companies will share in product net profits.
Wowwwzaaaa!!!
Oxycodone Hydrochloride extended release (generic version of OxyContin®)
On September 20, 2017, the Company filed an ANDA with the FDA for generic version of OxyContin® (extended release Oxycodone Hydrochloride). OxyContin® is approved for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. IMS reported approximately $2.3 billion in revenue for OxyContin® and its equivalents in 2016. The FDA requested additional information relating to this filing, compliance with which would require significant resources. Development of this product has been reinitiated with a target filing in Q1 2023
YES!!!! Awesome !!!! ELTP is growing faster than I thought.
This is another good news! Thank you for keeping us (LONGS) updated.